Clinical Trial

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-03
notable Trial sites expanded: 0 -> 3 locations 2026-04-03
Trial Details
NCT Number NCT07137338
Lead Sponsor Rocket Pharmaceuticals Inc.
Conditions Dilated Cardiomyopathy (DCM)
Enrollment 8 participants
Start Date 2026-06
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-30